Completed PHASE1 INTERVENTIONAL 1-arm NCT00733187

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

A Pharmacokinetic Study to Evaluate the Effect of Food on the Oral Bioavailability and Effect of Diurnal Variation on the Pharmacokinetics of ABT-869

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Advanced Solid Tumors

Interventions ABT-869

Updated 7 times since 2017 Last updated: Nov 17, 2017 Started: Feb 28, 2009 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00733187, this PHASE1 trial focuses on Advanced Solid Tumors and remains completed. Sponsored by AbbVie (prior sponsor, Abbott), it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Dec 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.